Status:
TERMINATED
Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients
Lead Sponsor:
University of Vermont
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
The adaptive immune response, consisting of antiviral T and B cells, is critical for providing protection against viruses such as SARS-CoV-2, both during an active infection and later following a subs...
Detailed Description
Since December 2019, the novel coronavirus (SARS-CoV-2) and associated COVID-19 illness has spread worldwide. Globally, there are \>86 million infections and over 1.8 million confirmed deaths, with th...
Eligibility Criteria
Inclusion
- Adult (≥18 years old) at the time of consent
- Positive COVID-19 PCR test result
Exclusion
- Expected death or withdrawal of life-sustaining treatments within 3 days
- Hemoglobin ≤7.0 at the time of consent
- Unable to provide consent and no legally authorized representative (LAR) identified or reached by phone
- Pregnant
- Incarcerated
- Physician declines patient enrollment (attending physician or study physician)
- Patient or LAR do not consent to participate in the study
Key Trial Info
Start Date :
February 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT04892797
Start Date
February 3 2021
End Date
June 30 2023
Last Update
May 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Vermont
Burlington, Vermont, United States, 05405